<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Carbapenem-resistant &lt;i&gt;E. coli&lt;/i&gt;, &lt;i&gt;K. pneumoniae&lt;/i&gt;, and other Enterobacterales (CRE)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Carbapenem-resistant
       <i>
        E. coli
       </i>
       ,
       <i>
        K. pneumoniae
       </i>
       , and other Enterobacterales (CRE)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Carbapenem-resistant
        <i>
         E. coli
        </i>
        ,
        <i>
         K. pneumoniae
        </i>
        , and other Enterobacterales (CRE)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Quale, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Denis Spelman, MBBS, FRACP, FRCPA, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David C Hooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carbapenem antibiotics have an important antibiotic niche in that they retain activity against the chromosomal cephalosporinases and extended-spectrum beta-lactamases found in many gram-negative pathogens [
         <a href="#rid1">
          1,2
         </a>
         ]. The emergence of carbapenem-hydrolyzing beta-lactamases has threatened the clinical utility of this antibiotic class and brings us a step closer to the challenge of "extreme drug resistance" in gram-negative bacilli [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         This topic addresses issues related to carbapenem-resistant Enterobacterales (CRE). Enterobacterales that produce penicillinases and cephalosporinases are discussed in detail separately, as are carbapenem-resistant gram-negative bacilli that are not of the Enterobacterales order. (See
         <a class="medical medical_review" href="/z/d/html/469.html" rel="external">
          "Extended-spectrum beta-lactamases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3150.html" rel="external">
          "Acinetobacter infection: Treatment and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13961.html" rel="external">
          "Stenotrophomonas maltophilia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1441333066">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2478647266">
         <span class="h2">
          The Enterobacterales order
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enterobacterales is an order of bacteria that contains seven groups (ie, families) of gram-negative bacilli [
         <a href="#rid4">
          4,5
         </a>
         ]. Bacteria within the Enterobacterales families include several clinically relevant bacteria that commonly cause infections.
        </p>
        <p>
         The most clinically relevant families within the Enterobacterales order include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enterobacteriaceae
         <em>
         </em>
         family – This family includes at least 33 genera of bacteria, some of which cause human disease. The most notable are Escherichia
         <em>
         </em>
         (eg,
         <em>
          Escherichia coli
         </em>
         ), Klebsiella, Enterobacter, Citrobacter, Salmonella, and Shigella. Other relevant genera within this family include Cronobacter, Kluyvera, Leclercia, Raoultella, and Pseudoescherichia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Morganellacaeae
         <em>
         </em>
         family – Clinically relevant genera in this family include Proteus, Morganella, and Providencia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other families include genera such as Serratia, Erwinia, Hafnia, Peptobacterium, and Yersinia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2878735081">
         <span class="h2">
          Carbapenem-resistant Enterobacterales
         </span>
         <span class="headingEndMark">
          —
         </span>
         The United States Centers for Disease Control and Prevention (CDC) defines carbapenem-resistant Enterobacterales (CRE) as bacteria within the Enterobacterales order that are resistant to at least one carbapenem (ie,
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         , doripenem, or
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ) or that produce a carbapenemase enzyme [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Enterobacterales within the Morganellacaeae
         <em>
         </em>
         family (eg,
         <em>
          Proteus
         </em>
         spp,
         <em>
          Morganella
         </em>
         spp, and
         <em>
          Providencia
         </em>
         spp) are intrinsically resistant to
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         , so only
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         , and doripenem are used to determine if these organisms meet the CRE definition.
        </p>
        <p>
         CRE are often divided into carbapenemase-producing isolates and noncarbapenemase-producing isolates, based on the mechanism of resistance:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noncarbapenemase-producing CRE
         </strong>
         – Many CRE isolates do not have carbapenemase genes [
         <a href="#rid6">
          6,7
         </a>
         ]. Usually, carbapenem resistance in these isolates is due to acquisition or upregulation of a beta-lactamase gene coupled with concomitant presence of a chromosomal mutation in a porin gene that limits the ability of carbapenems to enter the bacterium. The epidemiology of noncarbapenemase-producing CRE is discussed elsewhere. (See
         <a class="local">
          'Overall prevalence of CRE'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carbapenemase-producing CRE
         </strong>
         – In some CRE isolates, carbapenem resistance is due to the presence of carbapenemases. Carbapenemases are enzymes produced by the bacteria that inactivate carbapenem antibiotics and typically other beta-lactam antibiotics including penicillins and cephalosporins. The epidemiology of carbapenemase-producing CRE is discussed elsewhere. (See
         <a class="local">
          'Carbapenemases'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4227696620">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3155476015">
         <span class="h2">
          Overall prevalence of CRE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Globally, CRE rates vary widely with per-capita rates estimated to be highest in Russia, the eastern Mediterranean region, India, and Southeast Asia [
         <a href="#rid8">
          8,9
         </a>
         ]. In the United States, approximately 12,000 CRE infections are estimated to occur per year in hospitalized patients; estimated deaths in the United States in 2017 were 1100, and the attributable healthcare costs were $130 million [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Worldwide data regarding the proportion of CRE isolates that produce carbapenemases is limited, primarily due to lack of widespread carbapenemase testing. In the United States, approximately 30 percent of all CRE isolates produce carbapenemases; the remaining 70 percent of CRE isolates are carbapenem-resistant due to other mechanisms [
         <a href="#rid6">
          6,9
         </a>
         ]. Among United States CRE isolates resistant to every available carbapenem, up to 60 percent produce a carbapenemase [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H112879742">
         <span class="h2">
          Carbapenemases
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many different carbapenemases, and the prevalence of each varies geographically.
        </p>
        <p class="headingAnchor" id="H203066676">
         <span class="h3">
          Classifications and geographic distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         The carbapenemases are organized into different classes within the Ambler molecular classification system, which is a classification system for all beta-lactamases.
        </p>
        <p>
         Within the Ambler molecular classification system, beta-lactamases (including carbapenemases) are grouped based on their amino acid homology. Class A, C, and D beta-lactamases all share a serine residue in the active site, while Class B enzymes require the presence of zinc for activity (and hence are referred to as metallo-beta-lactamases [MBLs]).
        </p>
        <p>
         Beta-lactamases, including carbapenemases, are encoded from genes that reside on chromosomes or plasmids. Genes that reside on plasmids are often capable of transferring to other bacteria within the same species or to other genera, which can lead to rapidly expanding outbreaks. In contrast, genes that reside on chromosomes cannot be transferred to other bacteria, and outbreaks of isolates that harbor chromosomal genes typically occur via spread of a single bacterial clone.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         C
         <strong>
          lass
         </strong>
         <strong>
          A beta-lactamases
         </strong>
         – This class includes penicillinases and cephalosporinases in the TEM, SHV, and CTX-M-type groups (which do not inactivate carbapenems) as well as additional groups that possess carbapenemase [
         <a href="#rid1">
          1,12
         </a>
         ]. Isolates within this class are characterized by their hydrolytic mechanism of beta-lactam inactivation, which requires an active-site serine at position 70 [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most clinically important carbapenemase within this class is the
         <em>
          Klebsiella pneumoniae
         </em>
         carbapenemase (KPC) group:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           Klebsiella pneumoniae
          </em>
         </strong>
         <strong>
          carbapenemases (KPC)
         </strong>
         — The genes that encode KPCs reside on transmissible plasmids and confer resistance to most beta-lactams [
         <a href="#rid14">
          14
         </a>
         ]. Because KPC genes reside on plasmids, they can be transmitted from
         <em>
          Klebsiella
         </em>
         to other genera, including
         <em>
          E. coli
         </em>
         , Citrobacter, Salmonella, Serratia,
         <em>
          Enterobacter
         </em>
         spp, and Pseudomonas [
         <a href="#rid15">
          15-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         KPC-possessing CRE have been increasingly recovered from multiple regions of the world, including North America, Europe, Asia, Australia, South America, and South Africa [
         <a href="#rid15">
          15,16,21-28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In the United States, KPCs are the most common carbapenemase [
         <a href="#rid29">
          29
         </a>
         ]. Since the first description of KPC from a clinical isolate of
         <em>
          K. pneumoniae
         </em>
         in the late 1990s in North Carolina, KPC-production has been identified in isolates from nearly every state [
         <a href="#rid14">
          14,30,31
         </a>
         ]. In a review of 4440 CRE isolates submitted to the United States Centers for Disease Control and Prevention (CDC) in 2017, 32 percent produced a carbapenemase and, among those, 88 percent possessed a KPC carbapenemase [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Several different variants of KPC enzymes have been identified, each of which may have different susceptibility profiles when tested in vitro [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Chromosomally-encoded Class A carbapenemases include
         <em>
          Serratia marcescens
         </em>
         enzyme (SME), NMC (non-metalloenzyme carbapenemase), and IMI (imipenem-hydrolyzing) beta-lactamases; SME have been recovered in a small number of
         <em>
          S. marcescens
         </em>
         isolates, while NMC and IMI have been identified among
         <em>
          Enterobacter
         </em>
         spp [
         <a href="#rid32">
          32-34
         </a>
         ]. Plasmid-encoded enzymes other than KPC include Guiana extended-spectrum (GES) and BKC-1; GES has been described in
         <em>
          P.
         </em>
         <em>
          aeruginosa
         </em>
         and
         <em>
          K. pneumoniae
         </em>
         ,
         <em>
         </em>
         and BKC-1 has been detected in
         <em>
          K. pneumoniae
         </em>
         isolates in Brazil [
         <a href="#rid12">
          12,14,35-37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Class B beta-lactamases
         </strong>
         — Class B beta-lactamases are also known as the metallo-beta-lactamases (MBLs). MBLs are named for their dependence on zinc for efficient inactivation of beta-lactams and all are carbapenemases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MBLs were initially described in Japan in 1991 [
         <a href="#rid38">
          38
         </a>
         ]. MBLs have since been described in other parts of Asia, Europe, North America, South America, and Australia [
         <a href="#rid39">
          39-44
         </a>
         ]. The greatest burden of MBLs is in South and Southeast Asia (eg, India, Pakistan, China), and MBLs are the predominate carbapenemase in India, Pakistan, and some eastern European countries (eg, Greece, Hungary, Serbia, Croatia) [
         <a href="#rid45">
          45
         </a>
         ]. The transfer of patients between hospitals and the increase in international travel may be important factors in the geographic dissemination of MBL genes [
         <a href="#rid39">
          39,40,46-48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are both naturally occurring and acquired MBLs. Naturally occurring MBLs are chromosomally encoded and have been described in
         <em>
          Aeromonas hydrophilia
         </em>
         ,
         <em>
          Chryseobacterium
         </em>
         spp, and
         <em>
          Stenotrophomonas maltophilia
         </em>
         [
         <a href="#rid39">
          39
         </a>
         ]. Acquired MBLs consist of genes encoded on integrons residing on large plasmids that are transferable between both species and genera [
         <a href="#rid13">
          13,46,49-53
         </a>
         ]. For example, in a hospital outbreak involving 62 patients, an MBL gene (
         <em>
          bla
         </em>
         -IMP-4) spread among seven different gram-negative genera (Serratia, Klebsiella, Pseudomonas, Escherichia, Acinetobacter, Citrobacter, and Enterobacter) [
         <a href="#rid49">
          49,54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most clinically important Class B carbapenemase is the New Delhi metallo-beta-lactamase (NDM-1):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          New Delhi metallo-beta-lactamase (NDM-1)
         </strong>
         – Isolates that produce NDM-1 carbapenemases are resistant to a number of antibiotics, including antibiotics to which other types of carbapenemase-producing isolates are susceptible (eg, newer beta-lactamase inhibitor combination antibiotics) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The gene encoding NDM-1 is embedded within a very mobile genetic element, and the pattern of spread appears to be more complex and more unpredictable than that of the gene encoding KPC [
         <a href="#rid56">
          56,57
         </a>
         ]. NDM-1 has been identified in Enterobacterales (eg,
         <em>
          K. pneumoniae
         </em>
         ,
         <em>
          E. coli
         </em>
         ,
         <em>
          Enterobacter cloacae
         </em>
         ) and non-Enterobacterales (eg, Acinetobacter) species [
         <a href="#rid58">
          58,59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The NDM-1 gene was first described in December 2009 in a
         <em>
          K. pneumoniae
         </em>
         isolate from a Swedish patient who had been hospitalized in India [
         <a href="#rid56">
          56
         </a>
         ]. Spread of this carbapenemase quickly ensued, and pathogens with NDM beta-lactamases have since been reported throughout the world, including in Asia, Europe, North America, the Caribbean, and Australia [
         <a href="#rid57">
          57,58,60-65
         </a>
         ]. The highest prevalence is in India, Pakistan, and Bangladesh, and high prevalence is also reported in Eastern European countries (eg, Romania, Poland, Serbia) [
         <a href="#rid45">
          45,66
         </a>
         ]. There have also been reports of patients who traveled internationally for health care procedures (so called "medical tourism") and presented with NDM-1 infections after returning to their home country [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In the United States, initial reports of NDM-1-producing Enterobacterales isolates were among patients who had traveled to India or Pakistan [
         <a href="#rid63">
          63
         </a>
         ]. However, by 2017, NDM-1 was found in 3.2 percent of CRE isolates submitted to the CDC's National Healthcare Safety Network, suggesting this beta-lactamase has become established in North America [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The first MBL discovered in 1991 was an IMP-1 MBL [
         <a href="#rid38">
          38
         </a>
         ]. Since then, additional groups of acquired MBLs have been identified: NDM, VIM, GIM, SPM, SIM, and other IMPs. There are a number of variants within each MBL group (for example, there are more than 50 IMP variants within the IMP group) [
         <a href="#rid39">
          39,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As a result of their dependence on zinc, MBLs can be inhibited by EDTA (an ion chelator); however, they are not inhibited by beta-lactamase inhibitors such as tazobactam, clavulanate, sulbactam, avibactam, vaborbactam, and relebactam.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Class C beta-lactamases
         </strong>
         – Class C beta-lactamases are also known as AmpC beta-lactamases. Bacteria within the Class C group do not inherently have significant carbapenemase activity. AmpC-producing isolates are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/469.html" rel="external">
          "Extended-spectrum beta-lactamases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         C
         <strong>
          lass D beta-lactamases
         </strong>
         – Class D beta-lactamases are also referred to as OXA-type enzymes because of their preferential ability to hydrolyze
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         rather than penicillin [
         <a href="#rid68">
          68
         </a>
         ]. OXA-type carbapenemases have been identified in CRE isolates, especially
         <em>
          K. pneumoniae
         </em>
         ,
         <em>
          E. coli
         </em>
         , and
         <em>
          E. cloacae
         </em>
         [
         <a href="#rid68">
          68-78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among the heterogeneous OXA group (which includes more than 100 enzymes), six subgroups have been identified with varying degrees of carbapenemase activity: OXA-23, OXA-24/OXA-40, OXA-48, OXA-51, OXA-58, and OXA-143  (
         <a class="graphic graphic_table graphicRef56259" href="/z/d/graphic/56259.html" rel="external">
          table 1
         </a>
         ). All groups are carried on transmissible plasmids except for OXA-51, which is chromosomally encoded (in
         <em>
          Acinetobacter baumannii
         </em>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most clinically important Class D carbapenemase is the OXA-48-type carbapenemase:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          OXA-48-type carbapenemase (OXA-48-type)
         </strong>
         – The first OXA-48-type carbapenemase was identified in a
         <em>
          K. pneumoniae
         </em>
         isolate in Turkey. Isolates have since been discovered in regions around the world including the United States, Europe, the Middle East, and Northern Africa [
         <a href="#rid28">
          28
         </a>
         ]. Based on available data, they have the highest prevalence in Turkey and other Mediterranean countries (eg, Spain, France, Romania) [
         <a href="#rid66">
          66
         </a>
         ]. In 2017, 1.6 percent of CRE in the United States were found to possess OXA-48-type carbapenemases [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21045526">
         <span class="h3">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carbapenemase-producing organisms can arise from previously carbapenemase-negative strains by acquisition of genes from other bacteria.
        </p>
        <p>
         Use of broad spectrum cephalosporins and/or carbapenems is an important risk factor for the development of colonization or infection with such pathogens [
         <a href="#rid47">
          47,54,79
         </a>
         ]. As an example, in one case-control study, 86 percent of patients with a KPC-producing Enterobacterales isolate (n = 91) had a history of cephalosporin use in the prior three months [
         <a href="#rid80">
          80
         </a>
         ]. However, prior receipt of antibiotics is not essential for acquisition of these strains [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         In addition to prior antibiotic use, other risk factors that have been associated with infection or colonization with a carbapenemase-producing organism include the following [
         <a href="#rid17">
          17,19,24,26,49,57,81-87
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior colonization or infection with a carbapenemase-producing organism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent travel (ie, within the prior 12 months) to countries with high prevalence of carbapenemase-producing organisms (eg, India, Greece, Pakistan, Turkey, Croatia), particularly if health care exposure occurred in the country (see
         <a class="local">
          'Classifications and geographic distribution'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trauma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Organ transplantation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mechanical ventilation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indwelling urinary or venous catheters
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overall poor functional status or severe illness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residence in a long-term care facility
        </p>
        <p>
        </p>
        <p>
         Limited data suggest that intestinal colonization with organisms carrying certain types of carbapenemases may be more likely to lead to bloodstream infections than colonization with other types of carbapenemases. Further data are necessary to confirm or refute this finding [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21045553">
         <span class="h3">
          Transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rapid spread of CRE around the world is due to a combination of molecular spread of carbapenemase genes among different strains of bacteria and the creation of environments where bacteria themselves can easily proliferate and spread to individuals.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transmission of carbapenemase genes from one bacterium to another
         </strong>
         – Carbapenemase genes can be transferred from carbapenemase-producing bacteria to other bacteria via vertical or horizontal transfer:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vertical transfer occurs when a carbapenemase gene is transferred from a parent bacterial cell to its offspring during reproduction. Because bacterial reproduction occurs via cell division and does not require two parent cells, daughter bacterial cells have a genetic profile that is essentially identical to their parent. Thus, daughter cells always inherit a carbapenemase gene if their parent is a carrier (unlike mammalian reproduction in which children have only a 50 percent chance of inheriting a specific gene from a parent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Horizontal carbapenemase gene transfer occurs when two different bacteria within close proximity to each other transfer genes. Horizontal carbapenemase transfer can occur within species or among different genera, as described above. (See
         <a class="local">
          'Classifications and geographic distribution'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Horizontal transfer typically occurs via transfer of a mobile genetic element (usually a plasmid) that harbors the carbapenemase gene. Once a carbapenemase-gene-carrying plasmid is acquired via horizontal transfer, it can further proliferate via vertical transmission during bacterial cell division (plasmids are copied during bacterial cell division, just as chromosomal DNA is copied).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because of the combination of vertical and horizontal transfer, carbapenemase genes can spread rapidly within bacteria-rich environments, such as patients' stool and community sewage systems. Furthermore, environments where broad-spectrum antibiotics are used (eg, hospitals, domestic livestock farms) can select for carbapenemase-producing isolates and thereby produce an environment ripe for proliferation of carbapenemase-producing organisms [
         <a href="#rid89">
          89-91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transmission of CRE to humans
         </strong>
         – Humans typically acquire CRE, like other gram-negative bacilli, by direct physical contact with the bacteria. People come into contact with the bacteria by touching either a person who has CRE or an environmental surface or substance contaminated with CRE. Once individuals acquire CRE, they often shed the bacteria in their stool and contaminate themselves and their surrounding environment [
         <a href="#rid39">
          39,53,92,93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are many reports of the introduction of carbapenemase-producing CRE into a country via hospitalization of an individual who recently returned from travel to a country with high prevalence of CRE [
         <a href="#rid57">
          57,87,94
         </a>
         ]. Once imported into a hospital, carbapenemase-producing CRE can proliferate [
         <a href="#rid17">
          17,49,82,84-86
         </a>
         ]. Identified sources of spread within hospitals include poor hand hygiene, hospital equipment such as stethoscopes and endoscopes, and colonized sinks and toilets [
         <a href="#rid41">
          41,53,95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Carbapenemase-producing bacteria have also been found to be prevalent in public water supplies in resource-poor countries and countries where over-the-counter antibiotics are common [
         <a href="#rid28">
          28,96
         </a>
         ]. For example, in India, contamination of the public water supply with NDM-1-positive bacteria is believed to contribute to high rates of human infection and colonization with these bacteria among residents and travelers to the country [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once introduced into a new environment, specific clones of carbapenemase-producing CRE can become well established within and outside the health care system [
         <a href="#rid41">
          41,49,54,97
         </a>
         ]. One particular clone of
         <em>
          K. pneumoniae
         </em>
         that carries the KPC gene has been reported as the predominant isolate across several geographic areas [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H92009070">
         <span class="h1">
          DETECTION OF CRE AND CARBAPENEMASES
         </span>
        </p>
        <p class="headingAnchor" id="H703830845">
         <span class="h2">
          CRE detection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of CRE isolates is usually not difficult because most isolates are typically identified using standard susceptibility results reported by microbiology laboratories. Specifically, CRE is confirmed by resistance of an Enterobacterales isolate to at least one carbapenem (except for
         <em>
          Proteus
         </em>
         ,
         <em>
          Morganella
         </em>
         , and
         <em>
          Providencia
         </em>
         , for which
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         resistance is intrinsic). Further discussion of the definition of CRE and the Enterobacterales order is found elsewhere. (See
         <a class="local">
          'Carbapenem-resistant Enterobacterales'
         </a>
         above and
         <a class="local">
          'The Enterobacterales order'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2672826668">
         <span class="h2">
          Carbapenemase detection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Identification of a CRE isolate does not always mean that the isolate produces a carbapenemase, but it should raise clinical suspicion. Furthermore, a carbapenemase-producing organism should be suspected in any patient with CRE who has previously grown a carbapenemase-producing isolate in culture or who has traveled within the prior 12 months to a country with a high prevalence of carbapenemase-producing bacteria, particularly if health care exposure occurred during travel [
         <a href="#rid98">
          98
         </a>
         ]. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
         Determining whether a carbapenemase is present can be important for infection control purposes and because it may in some cases affect antibiotic selection, as discussed elsewhere. (See
         <a class="local">
          'Antibiotic selection'
         </a>
         below.)
        </p>
        <p>
         Detecting the presence of a carbapenemase in a CRE isolate is not always straightforward, and microbiology laboratories vary in their practices. Standard susceptibility testing cannot confirm the presence of a carbapenemase because susceptibility patterns of carbapenemase-producing isolates and noncarbapenemase-producing CRE isolates can be identical [
         <a href="#rid32">
          32-34
         </a>
         ].
        </p>
        <p>
         However, CRE isolates that are also resistant to some of the newer extended-spectrum antibiotics may be suspected of harboring a specific carbapenemase. For example,
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         resistance may suggest a class B beta-lactamase. Rarely, CRE isolates retain susceptibility to
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         , a finding that is suggestive of a metallo-beta-lactamases (MBL) carbapenemase (although MBL-producing organisms are usually reported as resistant to aztreonam).
        </p>
        <p>
         Laboratories typically confirm carbapenemase production in a CRE isolate by performing phenotypic or genotypic tests that go beyond standard susceptibility testing:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenotypic tests
         </strong>
         – These tests utilize basic culture techniques that can be performed by typical microbiology laboratories. The tests detect specific characteristics of carbapemenase-producing organisms by using certain reagents or susceptibility testing methods [
         <a href="#rid39">
          39,46,99-107
         </a>
         ]. If positive, these tests can confirm the presence of a carbapenemase, but negative results may not reliably exclude their presence. The tests typically cannot distinguish between types of carbapenemases, but some phenotypic tests can help to differentiate class B beta-lactamases from others.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotypic tests
         </strong>
         – Unlike phenotypic tests, genotypic tests use molecular methods, such as polymerase chain reaction (PCR), to detect the presence of carbapenemase genes or gene mutations within a bacterial isolate. They are typically used to provide rapid results on isolates growing in blood or other sterile sites. The results of these tests often return before susceptibility testing and other phenotypic tests and may improve the use of appropriate therapy in infected individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because they detect specific genes, genotypic tests can identify specific carbapenemases, such as
         <em>
          Klebsiella pneumoniae
         </em>
         carbapenemase (KPC), New Delhi metallo-beta-lactamase (NDM-1), or OXA-48-type carbapenemases. Because genotypic tests are so specific, individual genotypic tests must be run for each individual carbapenemase. To overcome this issue, genotypic tests are often run as panels which allow multiple individual tests to be performed during a single cycle of testing. Such tests can screen at once for KPCs, individual MBLs, and OXA-type carbapenemases [
         <a href="#rid49">
          49,71,108-114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drawbacks of genotypic tests include negative results when a particular panel does not include a specific carbapenemase carried by the organism. Additionally, special equipment is necessary to run these tests.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          CLINICAL DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         CRE can cause clinical infections or asymptomatic colonization [
         <a href="#rid19">
          19,23
         </a>
         ]. Bloodstream infections, ventilator-associated pneumonia, urinary tract infection, and central venous catheter infections have been described [
         <a href="#rid41">
          41,49,53,105
         </a>
         ]. These organisms have been isolated from respiratory tract specimens, abdominal swabs, catheters, abscesses, urine, and surgical wounds [
         <a href="#rid23">
          23,41,53,54,105,115,116
         </a>
         ].
        </p>
        <p>
         The specific clinical syndromes are discussed in more detail in the corresponding topic reviews.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment of infection due to CRE is uncertain, and antibiotic options are limited  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). Management of patients with such infections should be done in consultation with an expert in the treatment of multidrug-resistant bacteria.
        </p>
        <p class="headingAnchor" id="H90205451">
         <span class="h2">
          Requesting specific susceptibility tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         When a CRE isolate is confirmed, including carbapenemase-producing Enterobacterales isolates, we typically request susceptibility testing for the following additional antibiotics to help guide antibiotic selection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agents that contain newer beta-lactamase inhibitors (
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         , and
         <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">
          imipenem-cilastatin-relebactam
         </a>
         ) [
         <a href="#rid117">
          117,118
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aminoglycosides (particularly
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         , if available)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluoroquinolones and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX; if not already reported)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          Colistin
         </a>
         or
         <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">
          polymyxin B
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          Aztreonam
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tetracyclines including
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         (if available)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          Fosfomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         (for urinary tract isolates)
        </p>
        <p>
        </p>
        <p>
         For suspected or confirmed metallo-beta-lactamase (MBL)-carrying organisms, testing for synergy between
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         and
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         should also be requested if possible [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H703062007">
         <span class="h2">
          Indications for empiric coverage of CRE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who are suspected of having an infection due to gram-negative bacilli, we only include coverage for CRE in selected high-risk cases. Specifically, we provide empiric therapy to patients with serious illness (eg, ventilator-associated pneumonia, intraabdominal infection) who have had exposure to an outbreak setting (eg, an intensive care unit with a CRE outbreak) or have had a prior culture at the site of infection that grew CRE. In such cases, an antibiotic regimen should be chosen that is directed toward the suspected isolate. Specific regimens are discussed below. (See
         <a class="local">
          'Antibiotic selection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H660900136">
         <span class="h2">
          Antibiotic selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         When a CRE infection is identified, we select or tailor the antibiotic regimen based on the susceptibility profile  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H315464206">
         <span class="h3">
          Isolates susceptible to standard-spectrum antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although susceptibility of CRE to traditional standard-spectrum antibiotics is uncommon, they can be used if the isolate is susceptible. Such antibiotics include fluoroquinolones and TMP-SMX. For urinary tract infections (UTIs), aminoglycosides,
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         are additional possibilities  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         Most CRE isolates are reported as nonsusceptible to traditional beta-lactams (eg,
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         ). Even if a CRE isolate is reported as susceptible to a traditional beta-lactam, we typically do not use the agent. We will treat with
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         in the unusual instance that an MBL-producing isolate is reported as susceptible to aztreonam, as discussed elsewhere [
         <a href="#rid120">
          120
         </a>
         ]. (See
         <a class="local">
          'Carbapenemase detection'
         </a>
         above.)
        </p>
        <p>
         Not uncommonly, CRE isolates are reported as susceptible to
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         and imipenem-cilastatin but resistant to
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         [
         <a href="#rid121">
          121
         </a>
         ]. Technically, these isolates are still categorized as CRE, as defined above (see
         <a class="local">
          'Carbapenem-resistant Enterobacterales'
         </a>
         above). Most of these isolates do not contain a carbapenemase, and we treat them with standard-spectrum antibiotics if possible [
         <a href="#rid10">
          10,98,121,122
         </a>
         ]. If standard-spectrum antibiotics are not an option, we cautiously use a carbapenem to which the isolate is susceptible. If these isolates test positive for a carbapenemase, we treat them as if they are resistant to all carbapenems regardless of susceptibility results [
         <a href="#rid98">
          98,123-125
         </a>
         ]. (See
         <a class="local">
          'Carbapenemase testing is positive'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluoroquinolones
         </strong>
         – For infections due to susceptible isolates, fluoroquinolones (eg,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ) can be used as monotherapy. Oral and intravenous formulations are available, and dosages are listed in the table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical studies of fluoroquinolones for treatment of CRE infections are limited, but the agents are commonly used to treat infections caused by carbapenem-susceptible Enterobacterales, and there is no reason to suspect they would be ineffective against fluoroquinolone-susceptible CRE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Unfortunately, the use of these agents for CRE infections is limited due to high rates of resistance. Depending on the study, resistance rates of CRE isolates to fluoroquinolones range from 25 to 98 percent [
         <a href="#rid39">
          39,53,126-128
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         – Like fluoroquinolones, trimethoprim-sulfamethoxazole (TMP-SMX) can be used as monotherapy to treat infections caused by susceptible isolates, and it can be given orally or intravenously. Dosages are listed in the table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical data regarding use of TMP-SMX to treat CRE infections are scarce, but we use it to treat susceptible CRE infections at any site.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Resistance to TMP-SMX is common among CRE isolates. In one study of 476 patients who had CRE infections from 18 hospitals in the United States, 338 (71 percent) had isolates that were nonsusceptible to TMP-SMX [
         <a href="#rid129">
          129
         </a>
         ]. Like other antibiotics, emergence of resistance while on therapy appears to hamper TMP-SMX's efficacy over time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aminoglycosides
         </strong>
         – Due to associated toxicity (eg, nephrotoxicity, ototoxicity), we typically avoid the use of aminoglycosides in favor of other active agents, if possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These agents can be used as monotherapy for susceptible CRE UTIs when other options are limited. They should not be used as single agents for infections outside the urinary tract due to lack of supportive clinical data in these settings [
         <a href="#rid98">
          98
         </a>
         ]. Dosages are listed in the table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For select patients with simple cystitis in whom complicated UTI has been ruled out, a single dose of an aminoglycoside is likely to be adequate and avoid associated toxicity. For patients with complicated UTIs, longer durations are often necessary, which may increase the risk of renal and ototoxicity, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">
          "Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Duration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Based on observational data, aminoglycosides appear to be effective for treatment of CRE UTIs. In a study of 87 patients hospitalized in New York with carbapenem-resistant
         <em>
          K. pneumoniae
         </em>
         bacteruria, treatment with an aminoglycoside was associated with a higher rate of microbiologic clearance (88 percent) compared with either
         <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">
          polymyxin B
         </a>
         (64 percent) or
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         (43 percent) [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CRE isolates are often susceptible to at least one aminoglycosides (eg,
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         ) [
         <a href="#rid131">
          131
         </a>
         ]. Plazomicin often retains activity against CRE isolates that are resistant to all other aminoglycosides. In the United States, plazomicin is approved for treatment of complicated UTIs in adults, but overall, clinical data using plazomicin to treat systemic infections due to carbapenem-resistant pathogens are limited [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          Nitrofurantoin
         </a>
         – Nitrofurantoin is an effective agent for simple cystitis, but it should not be used for complicated UTIs (eg, pyelonephritis) or for infections outside the urinary tract. The dosage is listed in the table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CRE isolates are sometimes resistant to
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         . For example, in a study of 81 carbapenem-resistant
         <em>
          E. coli
         </em>
         urine isolates from India, 37 (45 percent) were nonsusceptible [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          Fosfomycin
         </a>
         – We only use fosfomycin monotherapy (3 g orally as a single dose) to treat simple cystitis caused by
         <em>
          E. coli.
         </em>
         The dosage is found in the
         <em>
         </em>
         table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data, including randomized trials, suggest that
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         is an effective agent for simple cystitis, including that caused by multidrug-resistant gram-negative bacilli [
         <a href="#rid134">
          134
         </a>
         ]. However, for organisms other than
         <em>
          E. coli
         </em>
         , intrinsic resistance mechanisms may be present and lead to clinical failure [
         <a href="#rid135">
          135,136
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         According to United States and European standards, susceptibility results for
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         can be reported only for
         <em>
          E. coli
         </em>
         isolates [
         <a href="#rid137">
          137,138
         </a>
         ]. Furthermore, special microbiology methods are required to detect resistance. In vitro resistance appears to be uncommon among CRE
         <em>
         </em>
         isolates [
         <a href="#rid134">
          134,136,139-141
         </a>
         ]. However, emergence of resistance while on therapy has been documented [
         <a href="#rid134">
          134,142
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to its oral formulation,
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         is also available in some countries in an intravenous formulation (not available in the United States). Sufficient data are lacking for the use of intravenous fosfomycin for infections outside the urinary tract; available studies included the agent as part of combination regimens, and no discernible conclusions could be made [
         <a href="#rid143">
          143,144
         </a>
         ]. Furthermore, caution is warranted when using the agent for monotherapy outside the urinary tract because of its potential to develop resistance during treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         – We rarely use minocycline to treat CRE infections because data regarding the clinical use of minocycline to treat such infections are scarce; in a few case reports, minocycline was successful as monotherapy or as part of combination therapy in the treatment of health care-associated pneumonia, intra-abdominal infection, and bacteremia due to CRE [
         <a href="#rid145">
          145,146
         </a>
         ]. The dosage is found in the table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         susceptibility of CRE isolates varies, ranging from 12 percent susceptibility of
         <em>
          Klebsiella pneumoniae
         </em>
         carbapenemase (KPC)-producing isolates in Detroit, Michigan to 65 percent susceptibility of NDM- and OXA-48-type-producing isolates in India [
         <a href="#rid146">
          146,147
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H259570720">
         <span class="h3">
          Isolates resistant to standard-spectrum antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         For isolates that are resistant to standard-spectrum antibiotics, monotherapy with a newer extended-spectrum agent is preferred  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). These agents are generally well tolerated [
         <a href="#rid148">
          148-157
         </a>
         ].
        </p>
        <p>
         If such agents are not available, combination therapy with other agents is an alternative option, but we do not combine the newer extended-spectrum agents with other antibiotics except in rare circumstances, as described below. (See
         <a class="local">
          'Limited role of combination therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3300391771">
         <span class="h4">
          Carbapenemase testing not available
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibiotic selection for CRE isolates should be based on susceptibility results, whenever possible. As described above, susceptibility results can sometimes be used to determine the likelihood of specific carbapenemases and thereby guide therapy (see
         <a class="local">
          'Carbapenemase detection'
         </a>
         above). Additionally, local rates of carbapenemase production, if available, can be useful  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         In the United States, KPCs are the most common carbapenemases [
         <a href="#rid10">
          10,11
         </a>
         ]. Thus, unless we have reason to suspect another type of carbapenemase, we presume a KPC-mediated mechanism in CRE isolates and treat accordingly.
        </p>
        <p>
         If an MBL or OXA-48-type carbapenemase is suspected, we treat for the suspected carbapenemase (see
         <a class="local">
          'Carbapenemase testing is positive'
         </a>
         below). We have a high suspicion for such organisms in patients with CRE who have previously had a culture that grew an MBL- or OXA-48-type-producing isolate, have a susceptibility profile suggestive of these carbapenemases, or have traveled within the prior 12 months to a country with a high prevalence of such isolates, especially if medical care was received while there [
         <a href="#rid45">
          45
         </a>
         ]. Details regarding the epidemiology and risk factors for different types of carbapenemases is discussed above. (See
         <a class="local">
          'Carbapenemases'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4101196293">
         <span class="h4">
          Carbapenemase testing is negative
         </span>
         <span class="headingEndMark">
          —
         </span>
         Depending on local epidemiology, many CRE isolates do not produce a carbapenemase (or produce a carbapenemase that is not readily detected by local laboratory techniques). In the United States, approximately 40 percent of isolates resistant to all carbapenems do not harbor a carbapenemase, and these isolates usually retain susceptibility to the newer extended-spectrum agents discussed below  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid10">
          10,11
         </a>
         ]. (See
         <a class="local">
          'Carbapenemase testing is positive'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1231805405">
         <span class="h4">
          Carbapenemase testing is positive
         </span>
         <span class="headingEndMark">
          —
         </span>
         When microbiologic testing confirms the presence of a carbapenemase, antibiotic options are based on susceptibility results and the specific carbapenemase if standard-spectrum antibiotics are not an option  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). Standard-spectrum options are discussed above. (See
         <a class="local">
          'Isolates susceptible to standard-spectrum antibiotics'
         </a>
         above.)
        </p>
        <p>
         If our suggested carbapenemase-specific regimens are not options, combination therapy can be used. (See
         <a class="local">
          'Limited role of combination therapy'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          KPC
         </strong>
         – Preferred agents for KPC-possessing isolates are
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         or
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         ;
         <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">
          imipenem-cilastatin-relebactam
         </a>
         is also an option, although there are fewer supporting data for this agent  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ).
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         is an effective alternative, but susceptibility testing is infrequently performed for this agent and we favor preserving it for isolates with non-KPC-mediated resistance. For intraabdominal infections,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         are also acceptable alternatives. Dosages are listed in the table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          Ceftazidime-avibactam
         </a>
         (see table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ) for dosage)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This agent has more clinical data supporting its use than the other newer agents because it was developed earlier. Observational data of patients with KPC-producing organisms often compare the agent to
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         , either in combination or as monotherapy. Overall, studies suggest that
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         is associated with improved clinical cure rates and reduced overall mortality compared to other traditional standard-spectrum agents [
         <a href="#rid148">
          148,150,151,155-157
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         One observational study of 109 patients with KPC-producing
         <em>
          K. pneumoniae
         </em>
         bacteremia (97 percent due to KPC) found that patients treated with
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         were more likely to experience clinical success than patients treated with other therapies (OR 8.6; 95% CI, 1.6 to 43.4) [
         <a href="#rid150">
          150
         </a>
         ]. The other therapies consisted primarily of a carbapenem combined with either an aminoglycoside or
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         . There was no difference in documented severity of illness, comorbidities, or source of infection between the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Another observational study of 142 patients with KPC-producing bacteremia found that treatment with
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         was the only predictor of survival [
         <a href="#rid155">
          155
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In vitro data suggest that
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         is active against over 95 percent of KPC isolates [
         <a href="#rid158">
          158-160
         </a>
         ]. However, emergence of resistance to ceftazidime-avibactam during therapy has been reported and has been estimated to occur in approximately 20 percent of cases [
         <a href="#rid98">
          98,149,161
         </a>
         ]. Some data suggest that KPC-producing isolates that become resistant to ceftazidime-avibactam during therapy may develop lower MICs to
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         , although the clinical significance of this finding is unclear [
         <a href="#rid161">
          161
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          Meropenem-vaborbactam
         </a>
         (see table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ) for dosage)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Data suggest that
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         is effective for CRE infections, although clinical data specifically focused on treatment of KPC-producing organisms are scarce.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a randomized controlled trial of 47 patients with serious CRE infections,
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         was associated with higher rates of clinical cure (66 percent) compared with best available therapy (33 percent); mortality rates were lower in the meropenem-vaborbactam group as well, although the mortality differences did not reach statistical significance [
         <a href="#rid154">
          154
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In an observational study of 131 patients with CRE infections, clinical cure and 30-day mortality rates were similar between patients treated with
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         and those treated with
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         (69 versus 62 percent, and 12 versus 19 percent, respectively) [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Resistance to
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         appears to be exceedingly uncommon among KPC-producing isolates, with in vitro data reports of 100 percent susceptibility [
         <a href="#rid162">
          162,163
         </a>
         ]. Emergence of resistance during or after therapy has been estimated to occur in 3 percent of cases [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Imipenem-cilistatin-relebactam (see table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ) for dosage)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Clinical data evaluating this agent are scarce [
         <a href="#rid98">
          98,152
         </a>
         ]. However, in vitro data, clinical experience, and the stability of relebactam against KPC-producing isolates suggest that this agent should be effective for isolates that test susceptible [
         <a href="#rid158">
          158,159,164-167
         </a>
         ]. There are limited data available on the rate of emergent resistance to this agent during therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         (see table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ) for dosage)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         is a siderophore cephalosporin that maintains activity against all of the major carbapenemases [
         <a href="#rid168">
          168
         </a>
         ]. For CRE infections, data suggest that it is effective [
         <a href="#rid98">
          98,153
         </a>
         ]. In the United States, it is approved for the therapy of complicated UTIs as well as hospital-acquired and ventilator-associated pneumonia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         is likely to be as effective as the other agents listed above for treatment of CRE, we favor other options so cefiderocol can be preserved for MBL- or OXA-48-type producing isolates or carbapenem-resistant gram-negative pathogens other than Enterobacterales [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Against KPC-producing CRE isolates,
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         has been found to be active in vitro in over 95 percent of isolates [
         <a href="#rid168">
          168
         </a>
         ]. There are scant data available on the frequency of emergent resistance to this agent while on therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          Tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         (see table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ) for dosages)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Clinical data evaluating the use of these agents for treatment of CRE isolates are scarce. In vitro data suggest that susceptibility rates of CRE isolates for both agents are typically above 95 percent, with similar susceptibility rates for KPC-producing isolates [
         <a href="#rid160">
          160,162,169,170
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Carbapenems do not alter the activity of the
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         derivatives, including
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         . Therefore, active tetracycline derivatives should be expected to be no more or less effective against carbapenemase-producing isolates than noncarbapenemase isolates.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Both
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         have been found in randomized controlled trials for complicated intra-abdominal infections to achieve similar cure rates when compared with other appropriate agents [
         <a href="#rid171">
          171-173
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          Tetracycline
         </a>
         derivatives, including
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         , should not be used to treat UTIs or bacteremia due to low urine and blood concentrations.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">
          Omadacycline
         </a>
         should not be used to treat CRE infections due to data suggesting high levels of baseline resistance to this agent [
         <a href="#rid174">
          174
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          OXA-48-type
         </strong>
         – The preferred antibiotic for isolates with an OXA-48-type carbapenemase is
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ).
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         is an acceptable alternative. For intra-abdominal infections,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         are also acceptable alternatives based on limited susceptibility data [
         <a href="#rid169">
          169
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         OXA-48-type CRE isolates have high rates of resistance to
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         and imipenem-cilistatin-relebactam. There is uncertainty about the utility of these agents for OXA-48-type-producing isolates reported as susceptible to these agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Observational data support the use of
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         for treatment of infections caused Enterobacterales isolates with OXA-48-type carbapenemases [
         <a href="#rid157">
          157,175
         </a>
         ]. One study of 31 patients with hematologic malignancy and carbapenemase-producing
         <em>
          E. coli
         </em>
         bacteremia (19 with OXA-48-type and 12 with KPC carbapenemases) found higher clinical cure rates in patients who received ceftazidime-avibactam (86 percent) versus alternative active therapy (35 percent), and there was no difference in cure rates between OXA-48-type enzyme producers and KPC producers [
         <a href="#rid157">
          157,175
         </a>
         ]. Efficacy data for
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         are further described above in the section discussing treatment of KPC-producing isolates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In vitro data suggest that over 90 percent of OXA-48-type CRE isolates are susceptible to
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         [
         <a href="#rid160">
          160,164,165,168,169,176
         </a>
         ]. However, studies report susceptibility rates of only 15 to 33 percent for imipenem-cilistatin-relebactam and 45 to 50 percent for
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         [
         <a href="#rid164">
          164,165,167,176
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MBL
         </strong>
         – Antibiotics effective against isolates with MBL carbapenemases are limited because MBLs confer resistance to almost all beta-lactam-type antibiotics [
         <a href="#rid118">
          118
         </a>
         ]. Based on growing evidence, the combination therapy with
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         PLUS
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         is preferred  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). Another option is
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         . For intra-abdominal infections,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         are also acceptable alternatives based on limited susceptibility data [
         <a href="#rid169">
          169
         </a>
         ]. If no other options are available, we occasionally resort to combination therapy with a polymyxin and at least one additional agent. (See
         <a class="local">
          'Limited role of combination therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          Ceftazidime-avibactam
         </a>
         (as monotherapy),
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         , and imipenem-cilistatin-relebactam have no activity against MBL-producing organisms [
         <a href="#rid159">
          159,160,163,165,167
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          Ceftazidime-avibactam
         </a>
         PLUS
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         (doses are listed in the table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ))
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This combination has been successful in observational studies [
         <a href="#rid177">
          177-180
         </a>
         ]. In a study of 102 patients with bacteremia due to MBL-producing Enterobacterales, 30-day mortality was lower for those treated with the combination of
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         and
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         compared with those who received alternative therapy (19 percent versus 44 percent, respectively) [
         <a href="#rid180">
          180
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The combination of
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         PLUS
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         has a unique mechanism of action. MBL-producing organisms are intrinsically susceptible to aztreonam, but the organisms typically carry other resistance mechanisms (eg, ESBLs, AmpC beta-lactamases, OXA-48-type carbapenemases) that cause resistance to aztreonam [
         <a href="#rid120">
          120
         </a>
         ]. By adding avibactam (a newer beta-lactamase inhibitor), these resistance mechanisms are overcome and aztreonam regains its activity. The
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         component of ceftazidime-avibactam offers no additional benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There are no laboratory standards to identify the rates of resistance of CRE isolates to this combination of antibiotics.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         (see table  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ) for dosage)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Clinical experience in treating MBL-producing organisms with
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         is extremely limited. In vitro data suggest that susceptibility rates of these organisms to cefiderocol are around 60 percent [
         <a href="#rid168">
          168
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Efficacy data for
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         are further discussed above in the section discussing treatment of KPC-producing isolates.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3530901544">
         <span class="h4">
          Limited role of combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally avoid combination therapy for CRE infections; the lone exception is the combination of
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         and
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         for MBL-producing isolates, as discussed elsewhere (see
         <a class="local">
          'Carbapenemase testing is positive'
         </a>
         above). We generally do not combine the newer extended-spectrum agents with other antibiotics.
        </p>
        <p>
         In select circumstances, however, combination therapy may be reasonable. Specifically, for serious CRE infections for which standard-spectrum and newer extended-spectrum agents are not options, combination therapy may be used. When utilized, combination therapy should include two active agents, and we suggest continuation of both agents for the full course of therapy. Antibiotics that can be considered for combination therapy include the following if susceptibility is confirmed: a polymyxin (ie,
         <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">
          polymyxin B
         </a>
         or
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         ),
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         , aminoglycosides, and fluoroquinolones.
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          Meropenem
         </a>
         is sometimes used as part of combination therapy for isolates with MIC ≤8 (even if the isolate is reported as nonsusceptible). Eravacycline or tigecycline is typically combined with a second agent when they are being used for infections outside the abdomen. For
         <em>
          E. coli
         </em>
         infections, intravenous
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         is also an option in some countries.
        </p>
        <p>
         Prior to the availability of newer extended-spectrum antibiotics, polymyxins (ie,
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         or
         <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">
          polymyxin B
         </a>
         ) were commonly used as part of combination therapy for CRE infections. However, observational data and randomized controlled trials indicate increased mortality and renal toxicity associated with these agents relative to comparator agents [
         <a href="#rid98">
          98,148,150-152,154-157,175
         </a>
         ]. Concerns about the clinical effectiveness of polymyxins and the accuracy of susceptibility testing of polymixins against CRE isolates led American and European experts to eliminate or warn against susceptibility breakpoints for these agents [
         <a href="#rid137">
          137,138
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2469078427">
         <span class="h2">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regardless of the site of infection, the duration of therapy is identical to that for infections caused by carbapenem-susceptible Enterbacterales isolates. Specifically, the duration depends on the site of infection, which is discussed in detail in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">
          "Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Duration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">
          "Gram-negative bacillary bacteremia in adults", section on 'Duration and route of therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101694.html" rel="external">
          "Antimicrobial approach to intra-abdominal infections in adults", section on 'Duration of therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">
          "Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Duration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1651790293">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to the availability of newer extended-spectrum treatment options, patients with CRE infections had worse outcomes than patients infected with carbapenem-susceptible isolates [
         <a href="#rid89">
          89,181-183
         </a>
         ]. In a 2021 systematic review and meta-analysis of 50 studies, the risk of death was higher in individuals infected with CRE compared with carbapenem-susceptible Enterobacterales (relative risk [RR] 2.14; 95% CI, 1.85 to 2.48), and attributable mortality rate (available from eight studies) was 43 percent [
         <a href="#rid183">
          183
         </a>
         ]. The systematic review found conflicting results when analyzing whether delay in appropriate antibiotic therapy (a common occurrence with CRE) was the primary driver of mortality.
        </p>
        <p>
         Infections with carbapenemase-producing bacteria may have a particularly poor prognosis [
         <a href="#rid122">
          122,184-187
         </a>
         ]. Compared with patients who have bacteremia due to carbapenemase-negative CRE, patients with bacteremia due to carbapenemase-producing pathogens have been found to have a three- to five-fold higher mortality [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         Since the advent of newer extended-spectrum treatment options in 2015, beginning with
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         , it is unclear how attributable mortality has been affected. In one systematic review and meta-analysis of 11 studies comparing ceftazidime-avibactam with other treatment options, 30-day overall mortality was lower in the ceftazidime-avibactam group (RR 0.55, 95% CI 0.45 to 0.68); overall mortality in the ceftazidime-avibactam group was 26 percent and attributable mortality was not reported [
         <a href="#rid188">
          188
         </a>
         ]. Further discussion of outcomes with newer agents is found elsewhere. (See
         <a class="local">
          'Carbapenemase testing is positive'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          INFECTION PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection prevention and control interventions can be divided into interventions related to health care environments and those related to communities.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Healthcare settings
         </strong>
         – Hospitalized patients infected or colonized with carbapenemase-producing bacteria should be placed on contact precautions [
         <a href="#rid26">
          26,41,53,89,92,189,190
         </a>
         ]. Guidelines from the World Health Organization (WHO) and the Society of Healthcare Epidemiology of America recommend that inpatient contact precautions be continued for the duration of inpatient hospitalization [
         <a href="#rid89">
          89,190
         </a>
         ]. Contact precautions should also be maintained indefinitely (ie, during future hospitalizations) given the prolonged colonization with such organisms and the limited treatment options. Other standard measures, such as hand hygiene, minimizing the use of invasive devices, and antimicrobial stewardship, are necessary to infection prevention in general and likely to limit spread of resistant organisms. Careful attention to disassembling, cleaning, and disinfection of endoscopes and replacement of poorly designed sinks and toilets can be important as well [
         <a href="#rid95">
          95
         </a>
         ]. Further discussion of these interventions is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2672.html" rel="external">
          "Preventing infection transmitted by gastrointestinal endoscopy", section on 'Duodenoscopes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Screening high-risk patients to detect rectal colonization has been suggested as an important infection control modality [
         <a href="#rid39">
          39,53,92,93
         </a>
         ]. Several studies have documented reduced transmission of
         <em>
          Klebsiella pneumoniae
         </em>
         carbapenemase (KPC)-producing
         <em>
          K. pneumoniae
         </em>
         when comprehensive infection control protocols, including active surveillance, have been enacted [
         <a href="#rid191">
          191-194
         </a>
         ]. Although the impact of surveillance itself is difficult to assess, it may be useful in the setting of outbreaks due to carbapenem-resistant organisms, as recommended by the United States
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fhai%2Fpdfs%2Fcre%2FCRE-guidance-508.pdf&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLH8u4ja3BMFPP%2FAdd%2B1gXOynDGuCFvykqHl4ug%2BbLqlc4hZYLdR1bZX83J7SNKjgMA%3D%3D&amp;TOPIC_ID=471" target="_blank">
          Centers for Disease Control and Prevention
         </a>
         (CDC) or among patients with recent travel to areas where carbapenemases are prevalent. Molecular tests that detect genes associated with carbapenem resistance can aid in detection of rectal colonization, although availability of these assays varies by country [
         <a href="#rid195">
          195,196
         </a>
         ]. (See
         <a class="local">
          'Carbapenemase detection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Communities
         </strong>
         – Interventions for communities suffering from high prevalence of CRE infections should consider specific interventions such as reducing over-the-counter antibiotic availability and broad-spectrum antibiotic use in livestock. Proper separation of sewage from the public water supply and public bodies of water is important. Environmental surveillance for CRE isolates can help to determine the extent of spread [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2167201961">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/138962.html" rel="external">
          "Patient education: Carbapenem-resistant enterobacterales (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – Carbapenem-resistant Enterobacterales (CRE) are any Enterobacterales (eg,
         <em>
          E. coli
         </em>
         ,
         <em>
          Klebsiella
         </em>
         ,
         <em>
          Enterobacter
         </em>
         ,
         <em>
          Serratia
         </em>
         ) that are resistant to at least one carbapenem (ie,
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         , doripenem, or
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ) or that produce a carbapenemase enzyme.
         <em>
          Proteus
         </em>
         ,
         <em>
          Morganella
         </em>
         , and
         <em>
          Providencia
         </em>
         must be resistant to ertapenem, meropenem, and/or doripenem to be classified as CRE. (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CRE can be divided into non-carbapenemase-producing and carbapemenase-producing isolates. (See
         <a class="local">
          'Carbapenem-resistant Enterobacterales'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – CRE, including carbapenemase-producing isolates, are becoming increasingly prevalent around the world. The most clinically important carbapenemases are
         <em>
          Klebsiella pneumoniae
         </em>
         carbapenemases (KPC), metallo-beta-lactamases (MBLs), and OXA-48-type carbapenemases (OXA-48-type), and their epidemiology varies significantly by country. In the United States, KPCs are the most common carbapenemase. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Detection of carbapenemases
         </strong>
         – Susceptibility profiles cannot reliably differentiate carbapenemase-producing and noncarbapenemase producing CRE isolates. Definitive tests include advanced phenotypic tests as well as genotypic tests, but these types of tests are not widely used. (See
         <a class="local">
          'Carbapenemase detection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibiotic selection
         </strong>
         – Antibiotic selections for CRE are limited  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ). Our suggested regimens are based on an isolate's susceptibility profile and results of carbapenemase testing, if available  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Antibiotic selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Susceptible to standard-spectrum antibiotics
         </strong>
         – We use these agents if the isolate is susceptible  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). Such antibiotics include fluoroquinolones and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX). For urinary tract infections (UTIs), aminoglycosides,
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         are additional possibilities. (See
         <a class="local">
          'Isolates susceptible to standard-spectrum antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Resistant to all carbapenems
         </strong>
         – For isolates that are resistant to all standard-spectrum antibiotics as well as carbapenems, newer extended-spectrum agents are the primary options  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). For intra-abdominal infections,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         are acceptable alternatives  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Isolates resistant to standard-spectrum antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Carbapenemase testing not available
         </strong>
         – For these isolates, we use the susceptibility profile and the patient's risk factors to determine our level of suspicion for a KPC, MBL, or OXA-48-type carbapenemase; we treat presumptively for the suspected carbapenemase  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Risk factors'
         </a>
         above and
         <a class="local">
          'Carbapenemase testing not available'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Carbapenemase testing is negative
         </strong>
         – We suggest
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         , or
         <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">
          imipenem-cilastatin-relebactam
         </a>
         (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         is an alternative. (See
         <a class="local">
          'Carbapenemase testing is negative'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Carbapenemase testing is positive
         </strong>
         – Antibiotic regimens for these isolates are based on the specific carbapenemase  (
         <a class="graphic graphic_algorithm graphicRef141813" href="/z/d/graphic/141813.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Carbapenemase testing is positive'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For KPC isolates, we suggest
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          meropenem-vaborbactam
         </a>
         , or
         <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">
          imipenem-cilastatin-relebactam
         </a>
         (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ).
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         is an alternative.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For OXA-48-type isolates, we suggest
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         is an alternative.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For MBL isolates, we suggest treatment with a combination of
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         PLUS
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          Cefiderocol
         </a>
         is a possible alternative  (
         <a class="graphic graphic_table graphicRef140938" href="/z/d/graphic/140938.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of therapy
         </strong>
         – The duration of therapy depends on the site of infection and is no longer for CRE infection than for other infections. (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection prevention
         </strong>
         – Patients infected with CRE should be placed on contact precautions, and other standard infection-control measures should be followed. In outbreak settings, additional measures are recommended. (See
         <a class="local">
          'Infection prevention'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janda JM, Abbott SL. The Changing Face of the Family Enterobacteriaceae (Order: "Enterobacterales"): New Members, Taxonomic Issues, Geographic Expansion, and New Diseases and Disease Syndromes. Clin Microbiol Rev 2021; 34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnin RA, Jousset AB, Emeraud C, et al. Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales. Front Med (Lausanne) 2020; 7:616490.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention, Division of Healthcare-associated infections. CRE Technical information. https://www.cdc.gov/hai/organisms/cre/technical-info.html#Definition (Accessed on September 08, 2022).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf (Accessed on September 07, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399:629.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Antimicrobial resistance: Global report on surveillance, 2014. https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf?sequence=1&amp;isAllowed=y (Accessed on September 13, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabour S, Huang JY, Bhatnagar A, et al. Detection and Characterization of Targeted Carbapenem-Resistant Health Care-Associated Threats: Findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019. Antimicrob Agents Chemother 2021; 65:e0110521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis 2020; 20:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walther-Rasmussen J, Høiby N. Class A carbapenemases. J Antimicrob Chemother 2007; 60:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibata N, Doi Y, Yamane K, et al. PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 2003; 41:5407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navon-Venezia S, Chmelnitsky I, Leavitt A, et al. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006; 50:3098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villegas MV, Lolans K, Correa A, et al. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2007; 51:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007; 44:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miriagou V, Tzouvelekis LS, Rossiter S, et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hossain A, Ferraro MJ, Pino RM, et al. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother 2004; 48:4438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008; 52:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49:4423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoenigl M, Valentin T, Zarfel G, et al. Nosocomial outbreak of Klebsiella pneumoniae carbapenemase-producing Klebsiella oxytoca in Austria. Antimicrob Agents Chemother 2012; 56:2158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leavitt A, Navon-Venezia S, Chmelnitsky I, et al. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007; 51:3026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei ZQ, Du XX, Yu YS, et al. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother 2007; 51:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang LW, Buising KL, Jeremiah CJ, et al. Managing a nosocomial outbreak of carbapenem-resistant Klebsiella pneumoniae: an early Australian hospital experience. Intern Med J 2015; 45:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villegas MV, Lolans K, Correa A, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006; 50:2880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madni O, Amoako DG, Abia ALK, et al. Genomic Investigation of Carbapenem-Resistant Klebsiella pneumonia Colonization in an Intensive Care Unit in South Africa. Genes (Basel) 2021; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodworth KR, Walters MS, Weiner LM, et al. Vital Signs: Containment of Novel Multidrug-Resistant Organisms and Resistance Mechanisms - United States, 2006-2017. MMWR Morb Mortal Wkly Rep 2018; 67:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9:228.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Healthcare-associated infections; Tracking CRE. http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html (Accessed on October 16, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Queenan AM, Shang W, Schreckenberger P, et al. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother 2006; 50:3485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen BA, Bush K, Keeney D, et al. Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents Chemother 1996; 40:2080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pottumarthy S, Moland ES, Juretschko S, et al. NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg Infect Dis 2003; 9:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 in South Africa. J Antimicrob Chemother 2002; 49:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeong SH, Bae IK, Kim D, et al. First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea. Antimicrob Agents Chemother 2005; 49:4809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martins WM, Nicoletti AG, Santos SR, et al. Frequency of BKC-1-Producing Klebsiella Species Isolates. Antimicrob Agents Chemother 2016; 60:5044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Update: detection of a verona integron-encoded metallo-beta-lactamase in Klebsiella pneumoniae --- United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004; 42:5094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peleg AY, Franklin C, Bell J, Spelman DW. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J Antimicrob Chemother 2004; 54:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Carbapenem-resistant Klebsiella pneumoniae associated with a long-term--care facility --- West Virginia, 2009-2011. MMWR Morb Mortal Wkly Rep 2011; 60:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Göttig S, Hamprecht AG, Christ S, et al. Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-β-lactamase with increased carbapenemase activity. J Antimicrob Chemother 2013; 68:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossolini GM. Acquired metallo-beta-lactamases: an increasing clinical threat. Clin Infect Dis 2005; 41:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nouér SA, Nucci M, de-Oliveira MP, et al. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005; 49:3663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peleg AY, Bell JM, Hofmeyr A, Wiese P. Inter-country transfer of Gram-negative organisms carrying the VIM-4 and OXA-58 carbapenem-hydrolysing enzymes. J Antimicrob Chemother 2006; 57:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41:1549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houang ET, Chu YW, Lo WS, et al. Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-beta-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000. Antimicrob Agents Chemother 2003; 47:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkey PM, Xiong J, Ye H, et al. Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett 2001; 194:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiroto K, Ishii Y, Kimura S, et al. Metallo-beta-lactamase IMP-1 in Providencia rettgeri from two different hospitals in Japan. J Med Microbiol 2005; 54:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirakata Y, Izumikawa K, Yamaguchi T, et al. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother 1998; 42:2006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herbert S, Halvorsen DS, Leong T, et al. Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo- beta -lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia. Infect Control Hosp Epidemiol 2007; 28:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother 2011; 66:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53:5046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livermore DM, Andrews JM, Hawkey PM, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67:1569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol 2017; 17:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidjabat H, Nimmo GR, Walsh TR, et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase. Clin Infect Dis 2011; 52:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients - Rhode Island, March 2012. MMWR Morb Mortal Wkly Rep 2012; 61:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thoms-Rodriguez CA, Mazzulli T, Christian N, et al. New Delhi metallo-β-lactamase in Jamaica. J Infect Dev Ctries 2016; 10:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul D, Dhar Chanda D, Maurya AP, et al. Co-Carriage of blaKPC-2 and blaNDM-1 in Clinical Isolates of Pseudomonas aeruginosa Associated with Hospital Infections from India. PLoS One 2015; 10:e0145823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2017; 8:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walther-Rasmussen J, Høiby N. OXA-type carbapenemases. J Antimicrob Chemother 2006; 57:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalla-Costa LM, Coelho JM, Souza HA, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003; 41:3403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeon BC, Jeong SH, Bae IK, et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in korea. J Clin Microbiol 2005; 43:2241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turton JF, Ward ME, Woodford N, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006; 258:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006; 50:4114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bou G, Oliver A, Martínez-Beltrán J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000; 44:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez-Otsoa F, Gallego L, Towner KJ, et al. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J Clin Microbiol 2002; 40:4741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Héritier C, Dubouix A, Poirel L, et al. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J Antimicrob Chemother 2005; 55:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vahaboglu H, Budak F, Kasap M, et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006; 58:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67:1597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchaim D, Chopra T, Bhargava A, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012; 33:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deshpande P, Shetty A, Kapadia F, et al. New Delhi metallo 1: have carbapenems met their doom? Clin Infect Dis 2010; 51:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toleman MA, Biedenbach D, Bennett DM, et al. Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. J Antimicrob Chemother 2005; 55:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borgmann S, Wolz C, Gröbner S, et al. Metallo-beta-lactamase expressing multi-resistant Acinetobacter baumannii transmitted in the operation area. J Hosp Infect 2004; 57:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabaker K, Lin MY, McNally M, et al. Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: a multihospital study. Infect Control Hosp Epidemiol 2012; 33:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin MY, Lyles-Banks RD, Lolans K, et al. The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moser AI, Campos-Madueno EI, Sendi P, et al. Repatriation of a patient with COVID-19 contributed to the importation of an emerging carbapenemase producer. J Glob Antimicrob Resist 2021; 27:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falcone M, Tiseo G, Galfo V, et al. Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study). Clin Microbiol Infect 2022; 28:298.e1.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Guidelines for teh prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in health care facilities. file:///C:/Users/khall/Downloads/9789241550178-eng.pdf (Accessed on September 13, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Boeckel TP, Pires J, Silvester R, et al. Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science 2019; 365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mollenkopf DF, Stull JW, Mathys DA, et al. Carbapenemase-Producing Enterobacteriaceae Recovered from the Environment of a Swine Farrow-to-Finish Operation in the United States. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aubron C, Poirel L, Fortineau N, et al. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist 2005; 11:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gijón D, Curiao T, Baquero F, et al. Fecal carriage of carbapenemase-producing Enterobacteriaceae: a hidden reservoir in hospitalized and nonhospitalized patients. J Clin Microbiol 2012; 50:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson ME, Chen LH. NDM-1 and the Role of Travel in Its Dissemination. Curr Infect Dis Rep 2012; 14:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein L, Hunter JC, Arwady MA, et al. New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. JAMA 2014; 312:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh TH, Wang GC, Sng LH. Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore. J Clin Microbiol 2004; 42:5378.
          </a>
         </li>
         <li class="breakAll">
          Tamma PD, Aitken SL, Bonomo R, et al. IDSA Guidance on the treatment of antimicrobial-resistant gram-negative infections, Version 1.0. Published by IDSA, 3/7/2022. https://www.idsociety.org/practice-guideline/amr-guidance/ (Accessed on September 07, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vrioni G, Daniil I, Voulgari E, et al. Comparative evaluation of a prototype chromogenic medium (ChromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs. J Clin Microbiol 2012; 50:1841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan JJ, Wu JJ, Tsai SH, Chuang CL. Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-beta-lactamases in gram-negative bacilli. Diagn Microbiol Infect Dis 2004; 49:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picão RC, Andrade SS, Nicoletti AG, et al. Metallo-beta-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates. J Clin Microbiol 2008; 46:2028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girlich D, Halimi D, Zambardi G, Nordmann P. Evaluation of Etest® strips for detection of KPC and metallo-carbapenemases in Enterobacteriaceae. Diagn Microbiol Infect Dis 2013; 77:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SH, Jeong SH, Lee KJ. Evolution of TEM beta--lactamase genes identified by PCR with newly designed primers in Korean clinical isolates. Clin Microbiol Infect 2001; 7:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee K, Lim YS, Yong D, et al. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003; 41:4623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pitout JD, Gregson DB, Poirel L, et al. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43:3129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galani I, Rekatsina PD, Hatzaki D, et al. Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae. J Antimicrob Chemother 2008; 61:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Zwaluw K, de Haan A, Pluister GN, et al. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PLoS One 2015; 10:e0123690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan JJ, Hsueh PR, Ko WC, et al. Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001; 45:2224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodémont M, De Mendonça R, Nonhoff C, et al. Performance of the Verigene Gram-negative blood culture assay for rapid detection of bacteria and resistance determinants. J Clin Microbiol 2014; 52:3085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salimnia H, Fairfax MR, Lephart PR, et al. Evaluation of the FilmArray Blood Culture Identification Panel: Results of a Multicenter Controlled Trial. J Clin Microbiol 2016; 54:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monteiro J, Widen RH, Pignatari AC, et al. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 2012; 67:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuzon G, Naas T, Bogaerts P, et al. Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother 2012; 67:1865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart JC, Voets G, Scharringa J, et al. Detection of carbapenemase-producing Enterobacteriaceae with a commercial DNA microarray. J Med Microbiol 2012; 61:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holma T, Torvikoski J, Friberg N, et al. Rapid molecular detection of pathogenic microorganisms and antimicrobial resistance markers in blood cultures: evaluation and utility of the next-generation FilmArray Blood Culture Identification 2 panel. Eur J Clin Microbiol Infect Dis 2022; 41:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra AR, Pereira CA, Gales AC, et al. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother 2006; 50:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souli M, Kontopidou FV, Papadomichelakis E, et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital. Clin Infect Dis 2008; 46:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields RK, Clancy CJ, Press EG, Nguyen MH. Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2016; 60:3187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellais S, Mimoz O, Léotard S, et al. Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46:2032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davido B, Fellous L, Lawrence C, et al. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutgring JD, Balbuena R, Reese N, et al. Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelman MW, Bower CW, Grass JE, et al. Distinctive Features of Ertapenem-Mono-Resistant Carbapenem-Resistant Enterobacterales in the United States: A Cohort Study. Open Forum Infect Dis 2022; 9:ofab643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamma PD, Goodman KE, Harris AD, et al. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis 2017; 64:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulik CC, Fauntleroy KA, Jenkins SG, et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 2010; 48:2402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao Z, Lan F, Liu M, et al. Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant Enterobacteriaceae. Antimicrob Resist Infect Control 2017; 6:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guh AY, Bulens SN, Mu Y, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013. JAMA 2015; 314:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luterbach CL, Boshe A, Henderson HI, et al. The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. Open Forum Infect Dis 2019; 6:ofy351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55:5893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castanheira M, Davis AP, Mendes RE, et al. In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinnell JA, Dwyer JP, Talbot GH, et al. Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. N Engl J Med 2019; 380:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amladi AU, Abirami B, Devi SM, et al. Susceptibility profile, resistance mechanisms &amp; efficacy ratios of fosfomycin, nitrofurantoin &amp; colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections. Indian J Med Res 2019; 149:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito R, Mustapha MM, Tomich AD, et al. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene. mBio 2017; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott ZS, Barry KE, Cox HL, et al. The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates. J Clin Microbiol 2019; 57.
          </a>
         </li>
         <li class="breakAll">
          CLSI. M100-ED32: 2022 Performance standards for antimicrobial susceptbility testing, 32nd edition. http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED32:2022&amp;sbssok=CLSI%20M100%20ED32:2022%20TABLE%202A&amp;format=HTML&amp;hl=nitrofurantoin (Accessed on September 07, 2022).
         </li>
         <li class="breakAll">
          European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters, Version 12.0, 2022. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf (Accessed on September 07, 2022).
         </li>
         <li class="breakAll">
          Perween N, Sultan A, Akhtar A, et al. Nitrofurantoin and fosfomycin for the CRE adn MDR uropathogens: are the choices still same?. Internat J Commun Med and Pub Health. 202; 17(10). https://www.ijcmph.com/index.php/ijcmph/article/view/6834 (Accessed on September 07, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuon FF, Rocha JL, Formighieri MS, et al. Fosfomycin susceptibility of isolates with blaKPC-2 from Brazil. J Infect 2013; 67:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010; 35:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, et al. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 2012; 67:2777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014; 43:52.
          </a>
         </li>
         <li class="breakAll">
          Khatri A, Lobo S, Nog R, et al. Minocycline in the treatment of carbapenem-resistant Klebsiella pneumoniae. Abstract #364: 2017 Infectious Disease Society of America conference.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pogue JM, Neelakanta A, Mynatt RP, et al. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 2014; 59 Suppl 6:S388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veeraraghavan B, Pragasam AK, Bakthavatchalam YD, et al. Colistin-sparing approaches with newer antimicrobials to treat carbapenem-resistant organisms: Current evidence and future prospects. Indian J Med Microbiol 2019; 37:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis 2018; 66:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackley R, Roshdy D, Meredith J, et al. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis 2019; 68:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis 2020; 70:1799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 2018; 7:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karaiskos I, Daikos GL, Gkoufa A, et al. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. J Antimicrob Chemother 2021; 76:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakeam HA, Alsahli H, Albabtain L, et al. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis 2021; 109:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castón JJ, Lacort-Peralta I, Martín-Dávila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis 2017; 59:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulengowski B, Burgess DS. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center. Pathog Dis 2019; 77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang TY, Hsieh YJ, Kao LT, et al. Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. J Microbiol Immunol Infect 2022; 55:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jonge BL, Karlowsky JA, Kazmierczak KM, et al. In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother 2016; 60:3163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields RK, Chen L, Cheng S, et al. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castanheira M, Doyle TB, Kantro V, et al. Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Huband MD, Mendes RE, et al. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. Int J Antimicrob Agents 2018; 52:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canver MC, Satlin MJ, Westblade LF, et al. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lob SH, Karlowsky JA, Young K, et al. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017. J Med Microbiol 2020; 69:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papp-Wallace KM, Barnes MD, Alsop J, et al. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston BD, Thuras P, Porter SB, et al. Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents 2019; 53:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston BD, Thuras P, Porter SB, et al. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrissey I, Olesky M, Hawser S, et al. In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomkin J, Evans D, Slepavicius A, et al. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. JAMA Surg 2017; 152:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckmann C, Montravers P, Bassetti M, et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2:ii25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5:S354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher JC. Omadacycline: A Modernized Tetracycline. Clin Infect Dis 2019; 69:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alraddadi BM, Saeedi M, Qutub M, et al. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis 2019; 19:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castanheira M, Doyle TB, Collingsworth TD, et al. Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. J Antimicrob Chemother 2021; 76:3125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall S, Hujer AM, Rojas LJ, et al. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayol A, Nordmann P, Poirel L, Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2018; 73:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 2018; 73:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falcone M, Daikos GL, Tiseo G, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales. Clin Infect Dis 2021; 72:1871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014; 20:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villegas MV, Pallares CJ, Escandón-Vargas K, et al. Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries. PLoS One 2016; 11:e0154092.
          </a>
         </li>
         <li class="breakAll">
          Zhou R, Fang X, Zhang J, et al. Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis. BMJ Open, 2021. https://bmjopen.bmj.com/content/bmjopen/11/12/e054971.full.pdf (Accessed on September 13, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satlin MJ, Chen L, Patel G, et al. Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Righi E, Peri AM, Harris PN, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother 2017; 72:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin A, Fahrbach K, Zhao Q, Lodise T. Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis. Open Forum Infect Dis 2018; 5:ofy150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewardson AJ, Marimuthu K, Sengupta S, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis 2019; 19:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Huang HB, Peng JM, et al. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review and Meta-Analysis. Microbiol Spectr 2022; 10:e0260321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009; 58:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banach DB, Bearman G, Barnden M, et al. Duration of Contact Precautions for Acute-Care Settings. Infect Control Hosp Epidemiol 2018; 39:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009; 30:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010; 31:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010; 31:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayden MK, Lin MY, Lolans K, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis 2015; 60:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dortet L, Fusaro M, Naas T. Improvement of the Xpert Carba-R Kit for the Detection of Carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother 2016; 60:3832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonelli A, Arena F, Giani T, et al. Performance of the BD MAX™ instrument with Check-Direct CPE real-time PCR for the detection of carbapenemase genes from rectal swabs, in a setting with endemic dissemination of carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis 2016; 86:30.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 471 Version 68.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15673804" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The new beta-lactamases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17630334" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Carbapenemases: the versatile beta-lactamases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17918079" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A step closer to extreme drug resistance (XDR) in gram-negative bacilli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33627443" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The Changing Face of the Family Enterobacteriaceae (Order: "Enterobacterales"): New Members, Taxonomic Issues, Geographic Expansion, and New Diseases and Disease Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33553210" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33553210" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33553210" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35065702" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35065702" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34570648" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Detection and Characterization of Targeted Carbapenem-Resistant Health Care-Associated Threats: Findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32151332" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17595289" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Class A carbapenemases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14662918" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11257029" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16940107" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17261621" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17342651" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12654661" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15504876" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18227191" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16189140" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22290949" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Nosocomial outbreak of Klebsiella pneumoniae carbapenemase-producing Klebsiella oxytoca in Austria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17562800" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17145797" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26178306" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Managing a nosocomial outbreak of carbapenem-resistant Klebsiella pneumoniae: an early Australian hospital experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16870793" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34206235" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Genomic Investigation of Carbapenem-Resistant Klebsiella pneumonia Colonization in an Intensive Care Unit in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22000347" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Global spread of Carbapenemase-producing Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29621209" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Vital Signs: Containment of Novel Multidrug-Resistant Organisms and Resistance Mechanisms - United States, 2006-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19324295" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19324295" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17005839" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8878585" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12967501" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11864961" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16251340" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27216068" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Frequency of BKC-1-Producing Klebsiella Species Isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1901695" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Transferable imipenem resistance in Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15831827" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Metallo-beta-lactamases: the quiet before the storm?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20864922" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Update: detection of a verona integron-encoded metallo-beta-lactamase in Klebsiella pneumoniae --- United States, 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15528701" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15282242" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22012114" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Carbapenem-resistant Klebsiella pneumoniae associated with a long-term--care facility --- West Virginia, 2009-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23557929" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-β-lactamase with increased carbapenemase activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32690645" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16267726" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Acquired metallo-beta-lactamases: an increasing clinical threat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16127037" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16476724" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Inter-country transfer of Gram-negative organisms carrying the VIM-4 and OXA-58 carbapenem-hydrolysing enzymes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16267725" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12654674" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-beta-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11150665" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16192438" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Metallo-beta-lactamase IMP-1 in Providencia rettgeri from two different hospitals in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9687398" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17230397" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo- beta -lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21393184" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19770275" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20577157" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20705517" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22461311" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28449650" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Structure, Genetics and Worldwide Spread of New Delhi Metallo-β-lactamase (NDM): a threat to public health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21258100" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22717513" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients - Rhode Island, March 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21653305" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26927461" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : New Delhi metallo-β-lactamase in Jamaica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26714034" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Co-Carriage of blaKPC-2 and blaNDM-1 in Clinical Isolates of Pseudomonas aeruginosa Associated with Hospital Infections from India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27593176" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The global epidemiology of carbapenemase-producing Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882287" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16446375" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : OXA-type carbapenemases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12843104" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15872249" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16630258" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000742" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11158758" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10817708" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12454183" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15590718" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816400" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22499996" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : OXA-48-like carbapenemases: the phantom menace.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18086836" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22759550" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20964525" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : New Delhi metallo 1: have carbapenems met their doom?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983294" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15574470" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15262391" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Metallo-beta-lactamase expressing multi-resistant Acinetobacter baumannii transmitted in the operation area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23143355" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: a multihospital study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23946222" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34718203" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Repatriation of a patient with COVID-19 contributed to the importation of an emerging carbapenemase producer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34197935" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34197935" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31604207" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Global trends in antimicrobial resistance in animals in low- and middle-income countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27919894" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Carbapenemase-Producing Enterobacteriaceae Recovered from the Environment of a Swine Farrow-to-Finish Operation in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16201928" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22403422" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Fecal carriage of carbapenemase-producing Enterobacteriaceae: a hidden reservoir in hospitalized and nonhospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22419230" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : NDM-1 and the Role of Travel in Its Dissemination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25291580" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21478057" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15528748" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15528748" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22461675" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Comparative evaluation of a prototype chromogenic medium (ChromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15135493" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-beta-lactamases in gram-negative bacilli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18322055" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Metallo-beta-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24041554" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Evaluation of Etest®strips for detection of KPC and metallo-carbapenemases in Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11298153" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Evolution of TEM beta--lactamase genes identified by PCR with newly designed primers in Korean clinical isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14532193" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16000424" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18222954" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25798828" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11451678" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24899026" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Performance of the Verigene Gram-negative blood culture assay for rapid detection of bacteria and resistance determinants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26739158" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Evaluation of the FilmArray Blood Culture Identification Panel: Results of a Multicenter Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22232516" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Rapid detection of carbapenemase genes by multiplex real-time PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22604450" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Evaluation of a DNA microarray for the rapid detection of extended-spectrumβ-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22383444" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Detection of carbapenemase-producing Enterobacteriaceae with a commercial DNA microarray.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34350523" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Rapid molecular detection of pathogenic microorganisms and antimicrobial resistance markers in blood cultures: evaluation and utility of the next-generation FilmArray Blood Culture Identification 2 panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16377720" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18269335" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26926642" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12019134" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28630191" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcomeβ-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32540972" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35036469" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Distinctive Features of Ertapenem-Mono-Resistant Carbapenem-Resistant Enterobacterales in the United States: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28013264" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20484603" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21635663" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24890393" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Treating infections caused by carbapenemase-producing Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15917285" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28785404" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26436831" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30631796" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21968368" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29866862" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30786196" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31219082" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Susceptibility profile, resistance mechanisms&amp;efficacy ratios of fosfomycin, nitrofurantoin&amp;colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20129148" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28851843" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31340992" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31340992" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31340992" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31340992" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23639842" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Fosfomycin susceptibility of isolates with blaKPC-2 from Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20034765" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22782489" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19694767" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24183799" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24183799" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25371515" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31424014" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Colistin-sparing approaches with newer antimicrobials to treat carbapenem-resistant organisms: Current evidence and future prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29020404" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32094128" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28559250" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29893802" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31400759" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33058795" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30270406" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33249436" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34091006" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28392315" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31365075" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33678555" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26926648" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28031201" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31712207" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29510189" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31262761" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31976856" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29610205" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Relebactam Is a Potent Inhibitor of the KPC-2β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32152073" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30395986" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32718965" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31843999" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27851857" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23772043" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16080073" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31367739" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Omadacycline: A Modernized Tetracycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31484510" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34459890" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28167541" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Can Ceftazidime-Avibactam and Aztreonam Overcomeβ-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29165563" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29272413" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32427286" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24959688" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27104910" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27104910" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28167547" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27999023" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30046639" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31047852" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35377233" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19300408" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29321078" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Duration of Contact Precautions for Acute-Care Settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19301985" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20175685" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20370465" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25537877" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27021332" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Improvement of the Xpert Carba-R Kit for the Detection of Carbapenemase-Producing Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27345126" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Performance of the BD MAX™instrument with Check-Direct CPE real-time PCR for the detection of carbapenemase genes from rectal swabs, in a setting with endemic dissemination of carbapenemase-producing Enterobacteriaceae.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
